

Refined Microcystin Payloads Show Promising In-Vitro Efficacy, Paving Way for Next-Generation Variants

Simris Group AB, a pioneer in the development of novel, next-generation Antibody Drug Conjugate (ADC) payloads based on Microcystin (MC) variants, announces that one of its most promising variants has demonstrated in-vitro efficacy that is nearly comparable to a leading ADC for the treatment of HER2-positive breast cancer. These results demonstrate potential for further improvement and will act as a benchmark for further studies designed to guide the development of second-generation MC variants with improved properties.

Dr. Alexis Roberts-McIntosh, CEO of Simris, stated "Simris Group is pioneering the development of the next-generation ADC payloads by optimizing Microcystin (MC) variants that deliver enhanced efficacy and safety. Our initial focus is on improving the safety profile of MC payloads for the treatment of non-solid tumors. By addressing this critical need in oncology, Simris is taking the first step that will see us expand the therapeutic potential of our technology to a broader range of cancer types. Additionally, significant efforts are being directed toward the development of ADCs utilizing MC-dimers as payloads, which could further improve potency and expand therapeutic window of the future ADCs.

"We continue to make significant progress towards our key goal of generating the pre-clinical data package needed for an Investigational New Drug Application (IND), a key step before starting clinical development. Our research is also actively exploring the optimal positioning of linkers, the integration of spacer designs, and novel linker variations to maximize the performance and stability of the ADCs based on our novel proprietary payloads. We have progressed lead optimisation of specific payloads, resulting in significant high performance in relevant OATP*-expressing cells. We have established linker-payload synthesis in-house which significantly speeds up our research and development programme," concluded Dr Roberts-McIntosh.

Simris Group believes that its expertise and world leading cyanobacterial library will enable it to play a crucial role in the timely development of the next generation of ADCs that should significantly improve the treatment outcomes of cancer patients globally. Simris Group intends to achieve this goal by collaborating a broad range of strategic partners.

* Organic anion transporting polypeptides

Contact Details:

Dr Alexis Roberts-McIntosh
CEO Simris Group AB
Email: ir@simris.com
Mobile: +44 (0) 7940 585298
www.simrisgroup.com

About Simris Group AB (PUBL):

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments

[Refined Microcystin Payloads Show Promising In-Vitro Efficacy, Paving Way for Next-Generation Variants](#)